Abstract:A dual-response (near-infrared, alternating magnetic field) multifunctional nanoplatform was developed based on urokinase plasminogen activators (uPA)-loaded metal–organic-framework (MOF)-derived carbon nanomaterials (referred to below) for thrombolytic therapy. uPA loaded in mesoporous CFs could be released under the action of near-infrared (NIR)-mediated photothermy to achieve superficial thrombolysis. More importantly, with the assistance of alternating magnetic field (AMF), this system could also precisely heat the thrombosis in the deep tissue area. Quantitative experiments proved that the thrombolytic efficiency of this dual-response system at deep venous thrombosis was nearly 6 times than that of NIR alone. This is the first application that MOF-derived carbon nanomaterials in the field of targeted thrombolysis. To our delight, the MOF-derived carbon nanomaterials (CFs) not only maintained the drug-carrying capacity, but also endowed CFs with reliable magnetic targeting ability. More encouragingly, the CFs also showed extraordinary angiogenic performance, thus opening up the prospect of its clinical application.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.1c03134?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.1c03134</a>.Particle size distribution of CFs (Figure S1a). Stability of the CFs hydrodynamic size during different incubation periods with serum (Figure S1b). High-resolution XPS spectra of (a) Fe 2p, (b) O 1s, and (c) C 1s (Figure S2). The summary of nitrogen adsorption–desorption analysis of MOFs (Fe) and CFs samples (Table S1). Pore size distribution of (a) MOFs (Fe) and (b) CFs samples (Figure S3). VSM curve of at room temperature (Figure S4). The photothermal effect and magnetothermal effect of CFs (Figure S5). uPA release from after being placed in saline over 7 days (Figure S6). The thickness of pork (Figure S7a). Deep evaluation of the magnetic field attracting CFs using different thickness of pork (scale bar = 1 cm) (Figure S7b). SEM analysis of thrombolysis (scale bar = 2 μm) (Figure S8). Scanning electron microscopy (SEM) images and the elemental mapping data of the degradation of CFs at the thrombus site at (a) 20 min, (b) 40 min, and (c) 1 h (scale bar = 5 μm) (Figure S9). SEM images of RBCs treated with different concentrations of CFs (scale bar = 5 μm) (Figure S10). Cell viability of HSF and HUVECs treated with different concentrations of CFs for 24 h (Figure S11a). Cell viability with various concentrations of CFs, CFs + NIR, CFs + AMF for 12 and 48 h (Figure S11b). Cell viability of HUVECs cocultured with different concentrations of CFs and VEGF for various time as indicated above. (Error bars represent the standard deviation of six separate measurements) (Figure S12). Photos (clots are marked in blue circles, scale bar = 1 cm) of clots before and after treatment for 24 h (Figure S13). The amount of Fe in the major organs and blood after treatment for 7 days (Figure S14). Four indicators of coagulation in SD rats (Figure S15a). Some indexes of liver and kidney function in SD rats (Figure S15b). The average body weight of rats in each group during the treatment periods (Figure S16) (<a class="ext-link" href="/doi/suppl/10.1021/acsami.1c03134/suppl_file/am1c03134_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

A microthrombus-driven fixed-point cleaved nanosystem for preventing post-thrombolysis recurrence via inhibiting ferroptosis

Alleviating Recombinant Tissue Plasminogen Activator-induced Hemorrhagic Transformation in Ischemic Stroke via Targeted Delivery of a Ferroptosis Inhibitor

Thrombus Targeted Delivery of Urokinase and Ticagrelor for Thrombosis-related Diseases Treatment

Platelet membrane-functionalized hollow mesoporous Prussian blue nanomedicine for comprehensive thrombolytic management by targeted enhanced fibrinolysis and ROS scavenging

Dual-targeting Fucoidan-Based Microvesicle for Arterial Thrombolysis and Re-Occlusion Inhibition

Engineered Nanoplatelets for Targeted Delivery of Plasminogen Activators to Reverse Thrombus in Multiple Mouse Thrombosis Models

Endothelial Targeting of a Recombinant Construct Fusing a PECAM-1 Single-Chain Variable Antibody Fragment (scfv) with Prourokinase Facilitates Prophylactic Thrombolysis in the Pulmonary Vasculature

Engineered platelets-based drug delivery platform for targeted thrombolysis

Multi-enzyme mimetic iridium nanozymes-based thrombus microenvironment-modulated nanoplatform for enhanced thrombolytic therapy

Ultrasound-powered hydrogen peroxide-responsive Janus micromotors for targeted thrombolysis and recurrence inhibition

Cryo-Shocked Platelet Coupled with ROS-Responsive Nanomedicine for Targeted Treatment of Thromboembolic Disease.

Direct delivery of plasmin using clot-anchoring thrombin-responsive nanoparticles for targeted fibrinolytic therapy

Biomimetic Nanoplatelets to Target Delivery Hirudin for Site-Specific Photothermal/Photodynamic Thrombolysis and Preventing Venous Thrombus Formation

A Erythrocyte-Platelet Hybrid Membrane Coated Biomimetic Nanosystem Based on Ginsenosides and PFH Combined with Ultrasound for Targeted Delivery in Thrombus Therapy.

Shear force-ROS sequential responsive drug delivery system for improving cerebral thrombosis microcirculation and neurological function

Precisely co-delivery of protein and ROS scavenger with platesomes for enhanced endothelial barrier preservation against myocardial ischemia reperfusion injury

Thrombotic microenvironment responsive crosslinking cyclodextrin metal-organic framework nanocarriers for precise targeting and thrombolysis

Prophylactic Thrombolysis by Thrombin-Activated Latent Prourokinase Targeted to PECAM-1 in the Pulmonary Vasculature

Thrombin induces ACSL4-dependent ferroptosis during cerebral ischemia/reperfusion

Targeted Thrombolytic Therapy with Metal–Organic-Framework-Derived Carbon Based Platforms with Multimodal Capabilities

Construction of Ultrasound-Responsive Urokinase Precise Controlled-Release Nanoliposome Applied for Thrombolysis.